Skip to main content

Research Library

Metabolic Peptide Research: Incretins and Amylin Analogues

The incretin field moved from single-receptor to multi-receptor pharmacology in under a decade. These pages summarise what the published trials actually measured, and what remains unknown.

Guides in this category

RT Research: Triple Receptor Agonism Explained

RT is an investigational triple agonist at the GIP, GLP-1 and glucagon receptors. It is not approved anywhere and Phase 3 outcome and safety data is still accumulating.

Read guide

TZ Research: Dual GIP/GLP-1 Agonism Evidence

TZ is a dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and for chronic weight management in several jurisdictions. It has the most complete trial dataset of the current multi-receptor agents.

Read guide

SM Research: GLP-1 Evidence and Outcomes

SM is a GLP-1 receptor agonist approved for type 2 diabetes, chronic weight management and cardiovascular risk reduction in people with obesity and established cardiovascular disease. The STEP and SELECT programmes gave the class its first hard-outcome evidence, moving it beyond weight and glucose endpoints.

Read guide

Cagrilintide Research: Amylin Analogue Evidence

Cagrilintide is a long-acting amylin analogue investigated alone and in fixed combination with SM (CagriSema). Amylin is a pancreatic hormone co-secreted with insulin that signals satiety through a different route from GLP-1, which is why combining the two is of interest. It is not approved.

Read guide

How Incretin Peptides Work: Mechanisms of Action Explained

Understanding which receptor does what explains why dual and triple agonists outperform single-receptor drugs, and why side-effect profiles differ. This page is a mechanism reference, not a treatment guide.

Read guide

Incretin Side Effects: What the Trial Data Reports

Adverse event data for incretin drugs comes from large randomised trials and from post-marketing surveillance, which answer different questions. Gastrointestinal effects dominate trial data; rarer signals emerge later from real-world reporting. This page summarises what has been reported and how confident the evidence is.

Read guide

Combination Research: Why Multi-Pathway Agents Are Studied

Combination research in metabolic pharmacology means engaging more than one receptor system, either in a single molecule or as co-administered agents. The rationale is that appetite, satiety and energy expenditure are separate physiological levers. This page reviews what has been tested in trials — it is not a protocol page.

Read guide

Other categories

Research supply · Independent documentation and customer feedback

We accept · Multiple secure payment methods

  • Bank Transfer
  • Card via Wise
  • Card via Monzo

Your next research order

From reading to your next research kit.

Compare compounds and kit sizes, choose your selection, then review delivery and payment details at checkout.

Laboratory research only. Not for human consumption.

Verified SupplierPeptides LookupVerify
100

Independently checked

ScamAdviser Trust Score: 100/100

ScamAdviser rates regena.app as legitimate and safe. Check the live result yourself.

Verify on ScamAdviser
  • Tracked worldwide delivery

    4–10 business days from tracking. Delivery cost shown at checkout.

  • Card or bank transfer

    Review your total before payment. Payment is confirmed separately.